COR · Cencora, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $78.36B | $85.93B | $80.66B | $75.45B | $81.49B | $74.24B | $68.41B | $72.25B | $66.95B | $63.46B |
| Cost of Revenue | $74.77B | $82.86B | $77.76B | $72.39B | $78.93B | $71.83B | $65.88B | $69.78B | $64.68B | $61.16B |
| Gross Profit | $3.59B | $3.07B | $2.91B | $3.06B | $2.56B | $2.41B | $2.54B | $2.47B | $2.26B | $2.30B |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $1.98B | $1.80B | $1.67B | $1.60B | $1.47B | $1.38B | $1.39B | $1.40B | $1.30B | $1.32B |
| Total Operating Expenses | $2.11B | $1.59B | - | - | - | - | - | - | - | - |
| D&A | $259.82M | $278.49M | - | - | $113.63M | - | - | $110.11M | - | - |
| Operating Income | $1.14B | $760.45M | $867.65M | $1.04B | $706.25M | $672.48M | $553.26M | $822.88M | $670.13M | $560.52M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $459.04M | $142.51M | $206.53M | $211.24M | $126.73M | $140.74M | $45.86M | $180.39M | $129.62M | $83.92M |
| Net Income | $1.64B | $559.65M | $687.40M | $717.87M | $488.60M | $483.46M | $420.77M | $601.50M | $479.58M | $435.40M |
| EPS - Basic | $8.44 | $2.88 | $3.55 | $3.70 | $2.52 | $2.44 | $2.11 | $3.01 | $2.37 | $2.15 |
| EPS - Diluted | $8.40 | $2.87 | $3.52 | $3.68 | $2.50 | $2.42 | $2.09 | $2.98 | $2.35 | $2.13 |
Balance Sheet
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.18B | $1.75B | $4.36B | $1.98B | $3.22B | $3.13B | $2.07B | $2.87B | $2.59B | $1.54B |
| Accounts Receivable | $24.89B | $25.98B | $25.23B | $23.72B | $24.55B | $23.87B | $22.64B | $21.58B | $20.91B | $19.49B |
| Inventory | $20.01B | $24.08B | $20.49B | $18.97B | $20.51B | $19.00B | $17.63B | $18.65B | $17.45B | $16.96B |
| Accounts Payable | $51.88B | $56.06B | $54.72B | $50.11B | $49.91B | $50.94B | $46.32B | $47.74B | $45.84B | $42.73B |
| Current Assets | $53.14B | $54.15B | $52.24B | $46.53B | $49.99B | $47.72B | $44.16B | $44.86B | $42.80B | $39.99B |
| Total Assets | $81.65B | $78.36B | $76.59B | $71.19B | $69.05B | $67.10B | $63.87B | $64.69B | $62.56B | $58.77B |
| Current Liabilities | $56.13B | $59.13B | $57.82B | $53.33B | $54.51B | $54.28B | $49.76B | $50.77B | $48.83B | $45.07B |
| Long-term Debt | $12.18B | $7.58B | $7.54B | $7.09B | $5.94B | $3.81B | $4.18B | $4.19B | $4.15B | $4.67B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $3.40B | $1.91B | $1.51B | $1.01B | $226.58M | $645.94M | $1.08B | $911.70M | $522.00M | $281.69M |
| Retained Earnings | $8.49B | $6.97B | $6.53B | $6.40B | $5.79B | $5.42B | $5.13B | $4.82B | $4.32B | $3.69B |
Cash Flow
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($2.31B) | - | - | ($2.72B) | - | - | $885.16M | - | - |
| Investing Cash Flow | - | ($299.31M) | - | - | ($343.04M) | - | - | ($65.80M) | - | - |
| Financing Cash Flow | - | $43.20M | - | - | $3.21B | - | - | ($551.67M) | - | - |
| CapEx | - | $119.38M | - | - | $105.89M | - | - | $74.22M | - | - |
| Free Cash Flow | - | ($2.42B) | - | - | ($2.82B) | - | - | $810.94M | - | - |
Ratios
| Metric | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 4.6% | 3.6% | 3.6% | 4.1% | 3.1% | 3.2% | 3.7% | 3.4% | 3.4% | 3.6% |
| Operating margin | 1.5% | 0.9% | 1.1% | 1.4% | 0.9% | 0.9% | 0.8% | 1.1% | 1.0% | 0.9% |
| EBITDA margin | 1.8% | 1.2% | - | - | 1.0% | - | - | 1.3% | - | - |
| Net margin | 2.1% | 0.7% | 0.9% | 1.0% | 0.6% | 0.7% | 0.6% | 0.8% | 0.7% | 0.7% |
| Free cash flow margin | - | -2.8% | - | - | -3.5% | - | - | 1.1% | - | - |
| FCF / Net income | - | -4.33 | - | - | -5.78 | - | - | 1.35 | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 2.5% | 2.1% | 2.1% | 2.1% | 1.8% | 1.9% | 2.0% | 1.9% | 1.9% | 2.1% |
| Effective tax rate | 21.9% | 20.3% | 23.1% | 22.7% | 20.6% | 22.5% | 9.8% | 23.1% | 21.3% | 16.2% |
| Return on assets | 2.0% | 0.7% | 0.9% | 1.0% | 0.7% | 0.7% | 0.7% | 0.9% | 0.8% | 0.7% |
| Return on equity | 48.3% | 29.3% | 45.6% | 70.9% | 215.6% | 74.8% | 38.8% | 66.0% | 91.9% | 154.6% |
| Return on invested capital | 5.7% | 6.4% | 7.4% | 9.9% | 9.1% | 11.7% | 9.5% | 12.4% | 11.3% | 9.5% |
| Liquidity | ||||||||||
| Current ratio | 0.95 | 0.92 | 0.90 | 0.87 | 0.92 | 0.88 | 0.89 | 0.88 | 0.88 | 0.89 |
| Quick ratio | 0.59 | 0.51 | 0.55 | 0.52 | 0.54 | 0.53 | 0.53 | 0.52 | 0.52 | 0.51 |
| Cash ratio | 0.04 | 0.03 | 0.08 | 0.04 | 0.06 | 0.06 | 0.04 | 0.06 | 0.05 | 0.03 |
| Leverage | ||||||||||
| Debt / Equity | 3.59 | 3.97 | 5.00 | 7.00 | 26.20 | 5.90 | 3.86 | 4.59 | 7.94 | 16.57 |
| Debt / Assets | 0.15 | 0.10 | 0.10 | 0.10 | 0.09 | 0.06 | 0.07 | 0.06 | 0.07 | 0.08 |
| Debt / EBITDA | 8.69 | 7.30 | - | - | 7.24 | - | - | 4.49 | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 24.03 | 41.06 | 50.79 | 70.29 | 304.77 | 103.88 | 58.97 | 70.96 | 119.84 | 208.62 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.96 | 1.10 | 1.05 | 1.06 | 1.18 | 1.11 | 1.07 | 1.12 | 1.07 | 1.08 |
| Inventory turnover | 3.74 | 3.44 | 3.79 | 3.82 | 3.85 | 3.78 | 3.74 | 3.74 | 3.71 | 3.61 |
| Days sales outstanding | 116d | 110d | 114d | 115d | 110d | 117d | 121d | 109d | 114d | 112d |
| Days inventory outstanding | 98d | 106d | 96d | 96d | 95d | 97d | 98d | 98d | 98d | 101d |
| Days payable outstanding | 253d | 247d | 257d | 253d | 231d | 259d | 257d | 250d | 259d | 255d |
| Cash conversion cycle | -40d | -31d | -47d | -42d | -26d | -45d | -38d | -43d | -46d | -42d |
| Valuation | ||||||||||
| P / E | 37.4x | 117.7x | 88.8x | 75.6x | 89.9x | 93.0x | 116.3x | 68.9x | 76.6x | 75.2x |
| P / B | 18.1x | 34.6x | 40.5x | 53.6x | 193.6x | 69.7x | 45.1x | 45.5x | 70.5x | 116.1x |
| P / S | 0.8x | 0.8x | 0.8x | 0.7x | 0.5x | 0.6x | 0.7x | 0.6x | 0.5x | 0.5x |
| EV / EBITDA | 50.9x | 69.1x | - | - | 56.8x | - | - | 45.8x | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 3.8% | 5.5% | 8.7% | 10.3% | 12.8% | 10.9% | 7.8% | 15.0% | 11.5% | 9.9% |
| Revenue CAGR (3y) | 7.3% | 11.0% | 10.3% | 9.3% | 11.0% | 11.6% | 11.7% | 11.2% | 13.8% | 10.2% |
| Revenue CAGR (5y) | 9.8% | 10.3% | 12.2% | 9.7% | 11.2% | 10.4% | 9.6% | 9.7% | 9.2% | 9.1% |
| Gross profit growth (YoY) | 17.3% | 20.1% | 20.6% | 20.6% | 3.6% | 6.5% | 10.6% | 15.0% | 12.4% | 2.7% |
| Operating income growth (YoY) | 10.3% | 7.7% | 29.0% | 87.3% | -14.2% | 0.4% | -1.3% | 30.0% | 37.5% | -28.2% |
| Net income growth (YoY) | 128.6% | 14.5% | 42.2% | 70.6% | -18.8% | 0.8% | -3.4% | 25.4% | 17.8% | -20.5% |
| EPS growth (YoY) | 128.3% | 14.8% | 45.5% | 76.1% | -16.1% | 3.0% | -1.9% | 27.9% | 22.4% | -17.8% |
| EPS CAGR (3y) | 58.0% | 7.2% | 22.4% | 12.4% | 5.5% | 20.0% | -0.2% | 18.1% | 18.6% | -22.9% |
| EPS CAGR (5y) | 32.0% | 9.7% | 20.1% | -4.5% | 22.7% | 11.1% | 74.3% | 10.1% | 13.5% | 10.5% |
| FCF growth (YoY) | - | 14.2% | - | - | - | - | - | 27.8% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | 15.2% | - | - |
| Book value growth (YoY) | 235.5% | 742.2% | 133.5% | -6.5% | -75.1% | 23.7% | 284.5% | - | - | -48.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-09-30.
Business segments
$309.68B totalUSHealthcare Solutions$285.29B · 92.1%
International Healthcare Solutions$24.39B · 7.9%
Peer comparison
Same SIC group: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Comparing Cencora against the 5 most active filers in the same SIC group.
Dividends
$2.35/share trailing 12 months · +8.8% YoY
| Ex-date | Per share |
|---|---|
| May 15, 2026 | $0.6000 |
| Feb 13, 2026 | $0.6000 |
| Nov 14, 2025 | $0.6000 |
| Aug 15, 2025 | $0.5500 |
| May 16, 2025 | $0.5500 |
| Feb 14, 2025 | $0.5500 |
| Nov 15, 2024 | $0.5500 |
| Aug 9, 2024 | $0.5100 |
| May 9, 2024 | $0.5100 |
| Feb 8, 2024 | $0.5100 |
| Nov 10, 2023 | $0.5100 |
| Aug 10, 2023 | $0.4850 |
| May 11, 2023 | $0.4850 |
| Feb 9, 2023 | $0.4850 |
| Nov 10, 2022 | $0.4850 |
| Aug 12, 2022 | $0.4600 |
| May 13, 2022 | $0.4600 |
| Feb 11, 2022 | $0.4600 |
| Dec 1, 2021 | $1.2700 |
| Nov 12, 2021 | $0.4600 |
| Sep 29, 2021 | $1.2700 |
| Aug 13, 2021 | $0.4400 |
| Jun 29, 2021 | $1.2700 |
| May 14, 2021 | $0.4400 |